News >

Optimal Use With Adjuvant Endocrine Therapy Continues to Unfold in ER+ Breast Cancer

Caroline Seymour
Published: Monday, Jul 09, 2018

Alex E. Denes, MD

Alex E. Denes, MD

In 1995, the National Institutes of Health released a clinical alert encouraging oncologists to discontinue therapy with tamoxifen after 5 years in patients with estrogen receptor (ER)-positive early breast cancer, a decision that is still not understood to this day, explained Alex E. Denes, MD.

State of the Science Summit™ on Breast Cancer, Denes, associate professor of medicine, School of Medicine, Oregon Health and Science University, discussed the mixed results looking at the optimal duration of adjuvant endocrine therapy in postmenopausal women with breast cancer.

OncLive: What does the adjuvant landscape of ER-positive breast cancer for postmenopausal women look like?

Denes: The concept of adjuvant therapy is not a very new concept. Dr Bernard Fisher at the University of Pittsburgh hypothesized that breast cancer is a systemic disease, as opposed to a localized cancer, in a majority of women. He proposed that if we could eliminate the micrometastases these patients harbored, we could improve the cure rate.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication